ConvaTec Group PLC Director/PDMR Shareholding (7565F)
11 Marzo 2020 - 04:45PM
UK Regulatory
TIDMCTEC
RNS Number : 7565F
ConvaTec Group PLC
11 March 2020
11 March 2020
ConvaTec Group Plc
("ConvaTec" or "the Company")
Director/PDMR Shareholding
The Company announces the following change in the interests of
Directors in ordinary shares of 10 pence each in the share capital
of the Company ("Shares").
On 6 March 2020, Karim Bitar, the Company's Chief Executive
Officer and Frank Schulkes, the Company's Chief Financial Officer,
both Executive Directors, received an additional grant of shares in
accordance with the Company's remuneration policy approved by
shareholders, as a result of one third of their annual bonus being
paid out as deferred shares as follows; such shares to vest on the
third anniversary of grant:
Karim Bitar: 55,348
Frank Schulkes: 81,318
The average of the middle market quotations of a ConvaTec share,
derived from the London Stock Exchange Daily Official List for the
three consecutive days from 3 March to 5 March 2020 (inclusive) of
187.90 pence was used in determining the number of shares to be
granted under the deferred bonus provisions.
No consideration was paid for the grant of this award.
The attached notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
detail.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Karim Bitar
2 Reason for the notification
a) Position/Status CEO
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name ConvaTec Group Plc
b) LEI 213800LS272L4FIDOH92
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary shares of 10p each in ConvaTec Group Plc
financial instrument, GB00BD3VFW73
type of instrument
Identification code
b) Nature of the transaction Grant of restricted share award under bonus deferral subject
only to a time based vesting
condition
c) Price(s) and volume(s) Price(s) Volume(s)
N/A 55,348
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transaction 6 March 2020
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Frank Schulkes
2 Reason for the notification
a) Position/Status CFO
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name ConvaTec Group Plc
b) LEI 213800LS272L4FIDOH92
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary shares of 10p each in ConvaTec Group Plc
financial instrument, GB00BD3VFW73
type of instrument
Identification code
b) Nature of the transaction Grant of restricted share award under bonus deferral subject
only to a time based vesting
condition
c) Price(s) and volume(s) Price(s) Volume(s)
N/A 81,318
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transaction 6 March 2020
f) Place of the transaction Outside a trading venue
Enquiries
Analysts and Investors
Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625
ir@convatec.com
Media
Buchanan: Charles Ryland / Chris Lane / Vicky Haynes +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions, with
leading market positions in advanced wound care, ostomy care,
continence and critical care, and infusion care. ConvaTec's
products provide a range of clinical and economic benefits
including infection prevention, protection of at-risk skin,
improved patient outcomes and reduced total cost of care. To learn
more about ConvaTec, please visit www.convatecgroup.com where a
copy of this announcement can also be found.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHKFLBFBXLLBBZ
(END) Dow Jones Newswires
March 11, 2020 11:45 ET (15:45 GMT)
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Mar 2023 a Mar 2024